📰 The European Commission approved a Marketing Authorization for lazertinib plus amivantamab as a first-line treatment for adults with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitution mutations.

➡️ Read more:#NSCLC #lcsm
#NSCLC #lcsm